Skip to main content
NCBI home page
PLOS One logoLink to PLOS One
. 2023 Aug 1;18(8):e0289021. doi: 10.1371/journal.pone.0289021

Development of ankylosing spondylitis in patients with ulcerative colitis: A systematic meta-analysis

Aitao Lin 1,*,#, Yongyi Tan 1, Jinxia Chen 1, Xiaoyu Liu 2, Jinyu Wu 2,*,#
Editor: Antoine Fakhry AbdelMassih3
PMCID: PMC10393153  PMID: 37527250

Abstract

Background

Ulcerative colitis (UC) is a manifestation of inflammatory bowel disease (IBD), which can cause inflammation of the intestinal tract. Ankylosing spondylitis (AS) is an inflammatory disease of the sacroiliac joints. Many studies have found that some UC patients progress to AS. In this study, we conducted a literature search and meta-analysis to investigate the prevalence of AS among UC patients during follow-up.

Methods

The studies related to the AS among patients with UC were obtained from PubMed, Web of Science, Embase, and Cochrane Library databases since its inception-December 2022. The literature was screened strictly according to inclusion and exclusion criteria. Forest plots were used to detect the overall incidence of AS in UC and to compare the risk ratios for the development of AS in the UC. The heterogeneity of studies was assessed using I2 statistical methods.

Results

1) 17 studies with 98704 UC patients were included. 2)700 UC patients developed AS during follow-up (1.66%, 95% CI: 0.89–2.62%). Human leukocyte antigen B27 (HLA-B27) was reported in 3 studies. HLA-B27 positivity was significantly higher than the incidence of HLA-B27 negativity in AS patients (68.29% vs 31.71%, P < 0.0001). There was significantly increased risk of AS development in HLA-B27 positive IBD patients (RR: 22.17, 95% CI: 11.79–41.66, P < 0.0001). 3)The definite follow-up time was reported in 12 studies (range: 0.3–40 years). After follow-up for ≥5 years, the incidence of AS among patients with UC was 1.75% (95% CI: 0.62–3.37%). Meanwhile, after follow-up for <5 years, the incidence of AS among patients with UC was 1.41% (95% CI: 0.65–2.37%) which was significant.

Conclusion

Patients with UC are more likely to develop AS in the future. Furthermore, the IBD patients are at a higher risk of AS who have positive HLA-B27. The incidence of AS increased with longer follow-up time.

1. Introduction

Ulcerative colitis (UC) is a form of inflammatory bowel disease (IBD)—an inflammatory disease of the gastrointestinal tract. In short, UC is a chronic autoimmune-related inflammatory disease. The clinical manifestations of UC mainly involve abdominal pain, diarrhea, and hematochezia [1]. It has long been recognized that UC may affect multiple organs of the body. The involvement of organs outside the gastrointestinal tract is often referred to as extraintestinal manifestations (EIMs) of UC, which mainly involves the hepatobiliary tract and the musculoskeletal system [2]. The literature suggests that the etiology of EIMs involves interactions between the environment and immune system [3]. Moreover, EIMs may be associated with the dysfunction of the intestinal flora and intestinal immune response [4]. Past studies have reported that approximately 30% of UC patients present with extra-intestinal manifestations such as the skeletal muscles and skin. Nevertheless, the pathogenesis of EIMs is unclear.

Ankylosing spondylitis (AS) is a chronic autoimmune disease that usually affects the sacroiliac joints and spinal attachments. Clinically, AS is characterized by inflammatory pain and stiffness of the back [5]. AS may involve axial or peripheral joints. According to past studies, 6% of AS is reported in adult UC patients, although it is rare among children [6–8]. Consistently, several AS patients have subclinical IBDs [9]. Similarly, the occurrence of AS among patients with UC is reportedly approximately 3% [10]. Considering that the UC and AS may manifest with similar pathogenesis, it is critical to explore the causal relationship between them to improve the level of diagnosis and treatment.

Human leukocyte antigen B27 (HLA-B27) is a characteristic test indicator for AS. However, the specificity and sensitivity of AS patients with HLA-B27 has been reportedly to be low in the presence of IBD [11]. Furthermore, the duration from the onset to diagnosis of AS can take several years. Therefore, early diagnosis of AS among patients with UC is of great significance. In this study, we conducted an extensive literature search and meta-analysis to investigate the prevalence of AS among UC patients during their follow-up period so as to provide an evidence-based basis for clinical practice.

2. Material and methods

The Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines was used to guidance the systematic meta-analysis [12].

2.1 Sources of information

The literatures about the development of AS in UC patients were collected from four foreign databases, which included PubMed, The Cochrane Library, Web of Science, and Embase since its inception-December 2022. In addition to, we also collected the relevant articles from conference abstracts and references.

2.2 Search strategy

“Ulcerative Colitis”, “Idiopathic Proctocolitis”, “Ankylosing Spondylitis”, “Bechterew’s Disease” and so on were used as subject terms to search the relevant literature. We used the following search strategy for the PubMed database (Fig 1. Search strategy of PubMed.).

Fig 1. Search strategy of PubMed.

Fig 1

Open in a new tab

2.3 Inclusion criteria

2.3.1 Object of study

Studies were included that patients with a clear diagnosis of UC who developed AS during follow-up. Used the 2010 Asia-Pacific Consensus [13] to diagnose UC patients. The 1984 modified New York criteria [14] was used to diagnose AS patients.

2.3.2 Types of research and language of publication

English language literature (including cross-sectional studies, cohort studies, case-control studies, etc.) on the occurrence of AS during UC follow-up were included.

2.4 Exclusion criteria

  • ① No follow-up study.

  • ② Reviews, case reports, animal and cell-based experiments, etc.).

  • ③ Repeatedly included literature, literature with incomplete data indicators or where complete information was not available.

2.5 Data extraction

2.5.1 Literature screening and data extraction

Two reviewers (TYY, CJX) independently screened the literature strictly according to the inclusion and exclusion criteria and extracted data by a standardized form. The literature was managed using NoteExpress software. Initially, after eliminating duplicates for inclusion, the primary screening was done by reading the title and abstract of the literature. And then full-text literature was analyzed in detail. If there was disagreement between the 2 reviewers in the literature screening or data extraction process, the decision was submitted to a 3rd reviewers (WJY).

2.5.2 Assessment of the quality of the literature

Case-control studies and cohort studies were evaluated for methodological quality using the Newcastle-Ottawa Scale (NOS) [15]. Cross-sectional studies using the AHRQ criteria. If 2 reviewers disagreed on the assessment of the quality of the literature, the decision was submitted to a 3rd reviewers (WJY). All included literature was of moderate to high quality.

2.6 Statistical analysis

The frequency of AS development in UC during follow-up was detected by a fixed or random-effects model. Literature heterogeneity was analysed using Revman 5.3 software and the R Statistical Software meta package. If P ≥ 0.10 and I2 ≤ 50%, the data were homogeneous across studies and were analysed using a fixed effects model. If P< 0.10 and/or I2 > 50%, we need to find the source of heterogeneity, or in cases where the source of heterogeneity was unclear, a random-effects model was used [16]. Besides, we estimated the risk ratio (RR) and its 95% confidence interval (CI) after followup for the AS development in UC patients. Using forest plots to summarize the data. Revman 5.3 software was used to draw funnel plots to evaluate publication bias.

3. Results

3.1 PROSPERO registration

Registration number: CRD42023405366.

3.2 Ethical approval

Our study did not involve human or animal experiments, which simply integrated results from other articles. Therefore, the study did not need to obtain ethical approval.

3.3 Literature search results

The databases search yielded 2033 relevant studies, and 17 studies were finally included for meta-analysis in strict accordance with the inclusion and exclusion criteria of this study (Fig 2. Literature screening process and results.) [17–33].

Fig 2. Literature screening process and results.

Fig 2

Open in a new tab

Note: *Databases searched and literature obtained are as follows: PubMed (n = 554), Web of Science (n = 497), The Cochrane Library (n = 68), Embase (n = 914).

3.4 Basic characteristics of the included studies

17 studies were included, which 2 studies were paediatric studies and the rest were adult studies. A total of 98704 UC patients were followed up (Table 1. Studies included in the meta-analysis.).

Table 1. Studies included in the meta-analysis.

First author/Date Country/Population Years UC/n UC-AS/n HLA-B27+/n (AS) Followup period
ØYVIND PALM/2001 Norway/A 1990–1993 273 7 11 5yrs.
Carol B/1974 NA/P 1960–1970 86 3 NA 10yrs.(md)
Raina Shivashankar/2014 USA/A 1970–2004 362 1 NA 40yrs.
Ignacio Marin-Jimenez/2015 Spain/A 2008–2010 130 2 NA 25mo
Jesús K/2017 Mexican/A 2014–2015 154 8 NA NA
Alvilde M. Ossum/2017 Norway/A 1990–1993 314 13 12 20yrs.
Morten L Halling/2017 Danish/A 1977–2013 31066 201 NA NA
Hoda M Malaty/2017 USA/A 1996–2009 357 7 NA 5.6yrs.(md)
Johan Burisch/2019 Denmark/A 2007–2016 8000 16 NA 5yrs.
Aimee Hiller/2019 Swiss/A 2016 1438 44 NA 13yrs.(md)
Hyo-Jeong Jang/2021 S Korean/P 2010–2017 35 0 NA 3.2yrs.(md)
C. Corrado/2011 Italian/A 2000–2010 593 8 NA 40.7 mo (md)
K. N. JALAN/1970 England/A 1950–1967 399 17 NA NA
C. Salvarani/2001 Italy、The Netherlands/A 1991–1993 98 2 5 50.3 mo(md)
Jung Min Bae/2016 S Korean/A 2009–2013 28197 130 NA NA
Asli Beslek/2009 Turkish/A 2005.04–2005.08 94 6 NA 4mo(md)
Timothy R. Card/2016 England/A 1987–2011 27108 235 NA NA
Open in a new tab

3.5 Meta-analysis

3.5.1 Meta-analysis of the prevalence of AS in UC patients during follow-up

The prevalence of AS among UC patients was detected by a random effects model. During the follow-up, 700 UC patients developed AS. The meta-analysis result showed that the prevalence of AS among UC patients was 1.66% (95% CI: 0.89–2.62%). But the heterogeneity was at a high level (I2: 93%). Due to the relatively small number of articles, data could not be removed to eliminate heterogeneity, and the source of heterogeneity was unclear (Fig 3. Forest plot of the meta-analysis of prevalence of AS among UC patients.).

Fig 3. Forest plot of the meta-analysis of prevalence of AS among UC patients.

Fig 3

Open in a new tab

3.5.2 Follow-up duration of UC and AS risk

12 studies mentioned the follow-up duration of UC (range: 0.3–40 years). The follow-up time duration was ≥ 5 years in 7 studies, while the follow-up time duration was < 5 years in 5 studies. UC patients whose follow-up period ≥ 5 years were more likely to develop AS than those with follow-up period < 5 years (1.75% vs 1.41%). The risk of AS development among UC patients was significantly higher in studies that had a longer follow–up period (P<0.000) (Fig 4. Forest plot of the meta-analysis of prevalence of AS among patients with UC with follow-up for ≥ 5years.; Fig 5. Forest plot of the meta-analysis of prevalence of AS among patients with UC with follow-up for ≤ 5years.).

Fig 4. Forest plot of the meta-analysis of prevalence of AS among patients with UC with follow-up for ≥ 5years.

Fig 4

Open in a new tab
Fig 5. Forest plot of the meta-analysis of prevalence of AS among patients with UC with follow-up for ≤ 5years.

Fig 5

Open in a new tab

3.5.3 HLA-B27 positivity and AS risk

3 studies mentioned the HLA-B27 positivity which included 1033 IBD patients. The HLA-B27 positivity of 94 IBD patients were detected in study. HLA-B27 positivity was significantly higher than HLA-B27 negativity in AS patients (68.29% vs 31.71%, P < 0.0001). There was significantly increased risk of AS development in HLA-B27 positive IBD patients (RR. 22.17, 95% CI: 11.79–41.66, P < 0.0001) (Fig 6. Forest plot of the risk ratios of AS development in IBD patients with HLA-B27.).

Fig 6. Forest plot of the risk ratios of AS development in IBD patients with HLA-B27.

Fig 6

Open in a new tab

Note: the left of “Events” means “HLA-B27+AS+”, the left of “Total” means “HLA-B27+AS-”; the right of “Events” means “HLA-B27-AS+”, the right of “Total” means “HLA-B27-AS-”.

4. Discussion

Our study results indicated that the prevalence of AS development in UC patients was 1.66%. Moreover, HLA-B27 positivity was significantly higher than HLA-B27 negativity in patients with AS (68.29% vs 31.71%, P < 0.0001), implying that HLA-B27 positivity is an important risk factor for the development of AS. On the other hand, the risk of AS development in UC patients with ≥5 years of follow-up was reported to be 1.75% (95% CI: 0.62–3.37%) and 1.41% (95% CI: 0.65–2.37%) in UC patients with <5 years of follow-up (P < 0.05), indicating that the risk of AS in UC patients may increase over time.

To the best of our knowledge, several studies have demonstrated a link between intestinal and joint inflammation [33–35]. Moreover, researchers have proposed the gut–joint axis hypothesis based on the pathogenesis of IBD and AS [36, 37]. Previously, Tito et al. reported a significant difference in the intestinal microbial composition between spondylarthritis patients without and with intestinal inflammation [38]. The gut microbes are an important aspect of the interaction between exogenous microbes and HLA-B27 [39]. Costello et al. concluded that dysbiosis of the gut flora may be a common pathogenesis of AS and intestinal inflammation [40]. In fact, 5%–10% of AS patients have concomitant IBD, and >70% of AS patients have subclinical intestinal inflammation. Consistently, a systematic review and meta-analysis revealed that AS occurs in 3% of patients with IBD [11]. In addition, up to 30% of patients with primary IBD develop joint symptoms, suggesting that the intestinal and joint inflammation may share a common pathogenesis.

HLA-B27 serves as the strongest genetic risk for AS, with 80–90% positivity reported in AS patients [40]. Ossum A. M. et al. concluded that the lower HLA-B27 positivity may affect the lower prevalence of AS [28]. Similarly, our study revealed that HLA-B27 positivity was significantly higher than HLA-B27 negativity in AS patients (68.29% vs 31.71%, P < 0.0001). Moreover, there was a significantly increased risk of AS development in HLA-B27-positive IBD patients (RR: 22.17, 95% CI: 11.79–41.66, P < 0.0001). However, HLA-B27 is less specific and less sensitive in patients with spondylitis presenting with IBD [11]. In clinical settings, more attention should be paid to HLA-B27 of IBD patients.

The follow-up duration is associated with the occurrence of AS in UC patients. The low prevalence of AS in the UC patients who were followed up may be attributed to the relatively short duration of follow-up. Our study results showed that, after follow-up for ≥5 years, the incidence of AS among patients with UC was 1.75% (95% CI: 0.62–3.37%). Meanwhile, at a follow-up for <5 years, the incidence of AS among patients with UC was 1.41% (95% CI: 0.65–2.37%) which was deemed significant. Moreover, a retrospective analyses conducted in Korea did not find the onset of AS during 3.2 years of follow-up among pediatric patients with UC [41]. In the present systematic meta-analysis, the incidence of AS was found to increase with the follow-up time. Similarly, Pamuk O N, et al concluded that the incidence of systemic lupus erythematosus increased with the follow-up time [42]. It can thus be concluded that the odds of developing AS in UC patients increases over time, which deserves the attention of clinicians.

There are, of course, limitations to our study. First, almost all included studies were retrospective case reports of AS in patients with UC. Second, the search literature was restricted to studies published in the English language. Many studies from other languages were not included in this study. Third, the therapy adopted for UC patients and their effects on AS development was also not studied. Finally, data collected on the gender or age of UC patients who developed AS was inadequate, which may have affected the calculation of the risk of developing AS in UC patients [43].

5. Conclusions

In patients with UC, the risk of developing AS is higher than in the general population. In addition, the HLA-B27 positive in IBD patients is a risk factor for AS which need follow-up. Finally, odds of developing AS in UC patients may increase over time.

Data Availability

All relevant data are within the paper.

Funding Statement

This work was supported by National Natural Science Foundation of China [grant numbers 82160878、81960866]. YES - Jinyu WU provided intellectual input and supervision during the study process and made a substantial contribution to manuscript drafting.

References

  • 1.Rosen MJ, Dhawan A, Saeed SA. Inflammatory bowel disease in children and adolescents. JAMA Pediatr2015;169(11):1053–60. doi: 10.1001/jamapediatrics.2015.1982 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 2.Jonathan P Segal gastroenterology registrar, Jean-Frédéric LeBlanc. Ulcerative colitis: an update. Clin Med (Lond). 2021, 21(2): 135–139. doi: 10.7861/clinmed.2021-0080 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 3.Kobayashi T, Siegmund B, Le Berre C, Shu Chen Wei, Marc Ferrante, Bo Shen et al. Ulcerative colitis. Nat Rev Dis Prim 2020;6:74. doi: 10.1038/s41572-020-0205-x [DOI] [PubMed] [Google Scholar]
  • 4.Vavricka SR, Schoepfer A, Scharl M, Peter L Lakatos, Alexander Navarini, Gerhard Rogler. Extraintestinal manifestations of inflammatory bowel disease. Inflammation Bowel Dis, 2015, 21:1982–92. doi: 10.1097/MIB.0000000000000392 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 5.Kaenkumchorn Tanyaporn, Wahbeh Ghassan. Ulcerative Colitis Making the Diagnosis.Gastroenterol Clin North Am, 2020;49(4):655–669. doi: 10.1016/j.gtc.2020.07.001 [DOI] [PubMed] [Google Scholar]
  • 6.Wyllie R, Hyams JS, Kay M, et al. Pediatric gastrointestinal and liver disease. 5th edition. Philadelphia: Saunders/Elsevier; 2015. [Google Scholar]
  • 7.Magro F, Gionchetti P, Eliakim R, Ardizzone S, Armuzzi A, Acosta M B, et al. Third European evidence-based consensus on diagnosis and management of ulcerative colitis. Part 1: definitions, diagnosis, extra-intestinal manifestations, pregnancy, cancer surveillance, surgery, and ileo-anal pouch disorders. J Crohns Colitis 2017;11(6):649–70. doi: 10.1093/ecco-jcc/jjx008 [DOI] [PubMed] [Google Scholar]
  • 8.Ranganathan V, Gracey E, Brown MA, Inman RD, Haroon N. Pathogenesis of ankylosing spondylitis-recent advances and future directions. Nat Rev Rheumatol (2017) 13:359–67. doi: 10.1038/nrrheum.2017.56 [DOI] [PubMed] [Google Scholar]
  • 9.Braun J, Sieper J. Ankylosing spondylitis. Lancet 2007;369:1379–90. doi: 10.1016/S0140-6736(07)60635-7 [DOI] [PubMed] [Google Scholar]
  • 10.Rudwaleit M, Baeten D. Ankylosing spondylitis and bowel disease. Best pract. res.Clin Rheumatol (2006) 20:451–71. doi: 10.1016/j.berh.2006.03.010 [DOI] [PubMed] [Google Scholar]
  • 11.Karreman M. C., Luime J. J., Hazes J.M.W., Weel A E A M. The Prevalence and Incidence of Axial and Peripheral Spondyloarthritis in Inflammatory Bowel Disease: A Systematic Review and Meta-analysis.Journal of Crohn’s and Colitis, 2017, 631–642. doi: 10.1093/ecco-jcc/jjw199 [DOI] [PubMed] [Google Scholar]
  • 12.Jacques P, Elewaut D, Mielants H. Interactions between gut inflammation and arthritis/spondylitis. Curr Opin Rheumatol (2010) 22:368–74. doi: 10.1097/BOR.0b013e3283393807 [DOI] [PubMed] [Google Scholar]
  • 13.Liberati A, Altman DG, Tetzlaff J, Mulrow C, Gøtzsche PC, Ioannidis John P A, et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration. Br. Med. J. 2009;339:b2700. doi: 10.1136/bmj.b2700 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 14.Choon Jin Ooi Kwong Ming Fock, Govind K Makharia Khean Lee Goh, Khoon Lin Ling Ida Hilmi, et al. The Asia-Pacific consensus on ulcerative colitis. J Gastroenterol Hepatol. 2010, 25(3):453–68. doi: 10.1111/j.1440-1746.2010.06241.x [DOI] [PubMed] [Google Scholar]
  • 15.Wells G, Shea B, O’connell D, et al. (2000) The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in metaanalyses. Eur JEpidemiol 25(9):603–605. [Google Scholar]
  • 16.Higgins JP, Thompson SG, Deeks JJ, Altman DG. (2003) Measuring inconsistency in meta-analyses. BMJ: British Medical Journal 327: 557. doi: 10.1136/bmj.327.7414.557 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 17.van der Linden S, Valkenburg HA, Cats A. Evaluation of diagnostic criteria for ankylosing spondylitis. A proposal for modification of the New York criteria. Arthritis Rheum 1984;27:361–8. doi: 10.1002/art.1780270401 [DOI] [PubMed] [Google Scholar]
  • 18.K N Jalan R Prescott J, Walker R J, Sircus W, McManus J P, Card W I . Arthropathy, ankylosing spondylitis, and clubbing of fingers in ulcerative colitis.Gut. 1970;11(9):748–54. doi: 10.1136/gut.11.9.748 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 19.Salvarani C., Vlachonikolis I. G., van der Heijde D. M., Fornaciari G Macchioni P, Beltrami M, et al. Musculoskeletal Manifestations in a Population-based Cohort of Inflammatory Bowel Disease Patients. Scand JGastroenterol, 2001;36(12):1307–13. doi: 10.1080/003655201317097173 [DOI] [PubMed] [Google Scholar]
  • 20.ØYVIND PALM, BJØRN MOUM, AKSEL ONGRE, Jan Tore Gran. Prevalence of Ankylosing Spondylitis and OtherSpondyloarthropathies Among Patients with Inflammatory Bowel Disease: A Population Study (The IBSEN Study). J Rheumatol. 2002. Mar;29(3):511–5. [PubMed] [Google Scholar]
  • 21.Lindsley C B, Sehaller J G. Arthritis associated with bowel disease in children.JPediatr.1974;84(1):16–20. doi: 10.1016/s0022-3476(74)80547-0 [DOI] [PubMed] [Google Scholar]
  • 22.Beslek Asli, Onen Fatos, Birlik Merih, Akarsu Mesut, Akar Servet, Sari Ismail, et al. Prevalence of spondyloarthritis in Turkish patients with inXammatory bowel disease. Rheumatol Int (2009) 29:955–957. doi: 10.1007/s00296-008-0811-5 [DOI] [PubMed] [Google Scholar]
  • 23.Shivashankar R, Edward V. Loftus Jr Tremaine W J, Scott Harmsen W Alan R Zinsmeister, Matteson Eric L. Incidence of Spondyloarthropathy in Patients with Ulcerative Colitis: A Population-based Study. J Rheumatol 2013;40;1153–1157. doi: 10.3899/jrheum.121029 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 24.Ignacio Marín-Jiménez a, Javier P. Gisbert b, José L. Pérez-Calle, Valle García-Sánchez4, Susana Tabernero5, Rosario García-Vicuña, et al. Incidencia a los 2 anos de nuevas enfermedades inflamatorias mediadas por inmunidad en la cohorte de pacientes con enfermedad inflamatoria intestinal del estudio AQUILES. Gastroenterol Hepatol. 2015;38(10):569–574. doi: 10.1016/j.gastrohep [DOI] [PubMed] [Google Scholar]
  • 25.Card Timothy R., Sine ad M. Langan, Thomas P. Chu C. Extra-Gastrointestinal Manifestations of Inflammatory Bowel Disease May Be Less Common Than Previously Reported. Dig Dis Sci. 2016;61(9):2619–26. doi: 10.1007/s10620-016-4195-1 [DOI] [PubMed] [Google Scholar]
  • 26.Bae J M, Choo J Y, Kim K J, Park K S. Association of inflammatory bowel disease with ankylosing spondylitis and rheumatoid arthritis: A nationwide population-based study. Mod Rheumatol. 2017,27(3):435–440. doi: 10.1080/14397595.2016.1211229 [DOI] [PubMed] [Google Scholar]
  • 27.Jesús K. Yamamoto-Furusho, Andrea Sarmiento-Aguilar. Joint involvement in Mexican patients with ulcerative colitis:a hospital-based retrospective study. Clin Rheumatol. 2018;37(3):677–682. doi: 10.1007/s10067-017-3834-z [DOI] [PubMed] [Google Scholar]
  • 28.Ossum A M, Palm Ø, Lunder A K, Cvancarova M, Banitalebi H, Negård A, et al. Ankylosing Spondylitis and Axial Spondyloarthritis in Patients With Long-term Inflammatory Bowel Disease: Results From 20 Years of Follow-up in the IBSEN Study. J Crohns Colitis. 2018;12(1):96–104. doi: 10.1093/ecco-jcc/jjx126 [DOI] [PubMed] [Google Scholar]
  • 29.Halling M L, Kjeldsen J, Knudsen T, Nielsen J, Hansen L K. Patients with inflammatory bowel disease have increased risk of autoimmune and inflammatory diseases. World J Gastroenterol 2017; 23(33): 6137–6146. doi: 10.3748/wjg.v23.i33.6137 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 30.Malaty H M, Wei Lo G H, Hou J K. Characterization and prevalence of spondyloarthritis and peripheral arthritis among patients with inflammatory bowel disease. Clin Exp Gastroenterol. 2017;10:259–263. doi: 10.2147/CEG.S136383 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 31.Burisch J, Jess T, Egeberg A. Incidence of Immune-Mediated Inflammatory Diseases Among Patients With Inflammatory Bowel Diseases in Denmark. Clin Gastroenterol Hepatol. 2019;17(13):2704–2712. doi: 10.1016/j.cgh.2019.03.040 [DOI] [PubMed] [Google Scholar]
  • 32.Hiller A, Biedermann L, Fournier N, Butter M, Vavricka S R, Ciurea A, et al. The appearance of joint manifestations in the Swiss inflammatory bowel disease cohort. PLoS One. 2019;14(4):e0211554. doi: 10.1371/journal.pone.0211554 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 33.Jang Hyo-Jeong, Hyo Rim Suh Sujin Choi, Suk Jin Hong Seung-Man Cho, Choi Kwang-Hae, et al. Severe Disease Activity Based on the Paris Classification Is Associated with the Development of Extraintestinal Manifestations in Korean Children and Adolescents with Ulcerative Colitis. J Korean Med Sci. 2021;36(44):e278. doi: 10.3346/jkms.2021.36.e278 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 34.Corrado C., Pica R., Avallone E.V., Cassieri C., De Carolis A., Paoluzi P., et al. Extraintestinal manifestations in a single centre cohort of chronic inflammatory bowel disease patients Digestive and Liver Disease 2011. 43 (S256) SUPPL. 3. [Google Scholar]
  • 35.Qaiyum Z, Lim M, Inman RD. The gut-joint axis in spondyloarthritis:Immunological, microbial, and clinical insights. Semin Immunopathol (2021) 43:173–92. doi: 10.1007/s00281-021-00845-0 [DOI] [PubMed] [Google Scholar]
  • 36.Speca S, Dubuquoy L. Chronic bowel inflammation and inflammatory joint disease:Pathophysiology. Joint Bone Spine (2017) 84:417–20. doi: 10.1016/j.jbspin.2016.12.016 [DOI] [PubMed] [Google Scholar]
  • 37.Brakenhoff L., van der Heijde D., Hommes D., Huizinga Tom W J, Fidder Herma H. The joint-gut axis in inflammatory bowel diseases. J. Crohns Colitis 4, 257–268. doi: 10.1016/j.crohns.2009.11.005 [DOI] [PubMed] [Google Scholar]
  • 38.Tito R., Cypers H., Joossens M., Varkas G, Praet L V, Glorieus E, et al. (2016). Brief report: Dialister as a microbial marker of disease activity in spondyloarthritis. Arthr. Rheum. 69, 114–121. doi: 10.1002/art.39802 [DOI] [PubMed] [Google Scholar]
  • 39.Gracey E, Vereecke L, McGovern D, Fröhling M, Schett G, Danese S, et al. Revisiting the gut-joint axis: Links between gut inflammation and spondyloarthritis. Nat Rev Rheumatol (2020) 16:415–33. doi: 10.1038/s41584-020-0454-9 [DOI] [PubMed] [Google Scholar]
  • 40.Costello M E, Ciccia F, Willner D, Warrington N, Robinson P C, Gardiner B, et al. Brief Report: Intestinal Dysbiosis in Ankylosing Spondylitis. Arthritis Rheumatol. 2015, 67(3):686–691. doi: 10.1002/art.38967 [DOI] [PubMed] [Google Scholar]
  • 41.Taurog JD, Chhabra A, Colbert RA (2016) Ankylosing spondylitis and axial spondyloarthritis. N Engl J Med 374:2563–2574. doi: 10.1056/NEJMra1406182 [DOI] [PubMed] [Google Scholar]
  • 42.Pamuk O N, Ali S M, Hasni S. Development of systemic lupus erythematosus in patients with immune thrombocytopenic purpura: A systematic meta-analysis. Autoimmun Rev. 2023;22(4):103297. doi: 10.1016/j.autrev.2023.103297 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 43.Van Praet L., Van den Bosch F. E., Jacques P., Jans L, Colman R, Glorieus E, et al. Microscopic gut inflammation in axial spondyloarthritis: a multiparametric predictive model. Ann. Rheum. Dis.2013, 72, 414–417. doi: 10.1136/annrheumdis-2012-202135 [DOI] [PubMed] [Google Scholar]

Associated Data

This section collects any data citations, data availability statements, or supplementary materials included in this article.

Data Availability Statement

All relevant data are within the paper.

Articles from PLOS ONE are provided here courtesy of PLOS

RESOURCES